文献速递消化道肿瘤与早癌食管胃疾病与幽门螺杆菌

芬兰男性中血清胃蛋白酶原1和抗幽门螺杆菌IgG抗体作为胃癌风险预测因子

Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.
PubMed 文献 · Aliment Pharmacol Ther · 2017-12-15

在芬兰男性吸烟者队列中,基线低血清胃蛋白酶原1(SPG1<25 μg/L)与胃癌风险升高相关(HR 2.68,95%CI 1.99-3.61)。联合幽门螺杆菌全菌及CagA血清学可将人群分为A-D四组,B、C、D组胃癌OR分别为1.79、3.85和6.35。单次SPG1联合幽门螺杆菌血清学可能有助于胃癌风险预测。

要点

  • 低SPG1(<25 μg/L)与胃癌风险升高相关(HR 2.68,95%CI 1.99-3.61)。
  • 幽门螺杆菌阳性且SPG1低者胃癌OR为3.85(95%CI 2.36-6.28)。
  • 幽门螺杆菌阴性且SPG1低者胃癌OR为6.35(95%CI 2.20-18.34)。

核心结论

  • 在芬兰男性吸烟者队列中,低SPG1与胃癌风险升高相关。
  • 单次SPG1联合幽门螺杆菌全菌及CagA血清学可提供潜在的胃癌风险预测。

研究设计与样本

  • 基于Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study的芬兰男性吸烟者队列,SPG1数据共21 895人。
  • 采用Cox比例风险模型估计胃癌HR及95%CI,调整潜在混杂因素。
  • 在3555例有抗幽门螺杆菌血清学的亚组中,用多因素logistic回归计算OR及95%CI。

主要发现

  • 基线后平均13.9年诊断329例胃癌。
  • 诊断前低SPG1与胃癌风险升高显著相关(HR 2.68,95%CI 1.99-3.61)。
  • B组(幽门螺杆菌阳性、SPG1正常)胃癌OR为1.79(95%CI 1.21-2.64)。
  • C组(幽门螺杆菌阳性、SPG1低)胃癌OR为3.85(95%CI 2.36-6.28)。
  • D组(幽门螺杆菌阴性、SPG1低)胃癌OR为6.35(95%CI 2.20-18.34)。

关键数值与推荐

  • 低SPG1定义为<25 μg/L。
  • A组(幽门螺杆菌阴性、SPG1正常)为参照组。
  • B组内CagA血清阳性者胃癌OR显著高于CagA血清阴性者(Pheterogeneity=0.01)。
  • B组和C组中,3年时重复SPG1水平未进一步分层胃癌风险。

临床怎么用

  • 原文结论认为单次SPG1联合幽门螺杆菌全菌及CagA血清学可提供潜在的胃癌风险预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Serum pepsinogen 1 (SPG1) and anti-Helicobacter pylori serology have been used for gastric risk stratification in Asia. AIM: To assess utility of these markers in a Western population. METHODS: SPG1 measurements were available for 21 895 Finnish male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. We used Cox proportional hazards models adjusted for potential confounders to estimate gastric cancer hazard ratios (HR) and 95% confidence intervals (95% CI) for low SPG1 (<25 μg/L). In a subset (n = 3555) with anti-H. pylori serology, these markers jointly defined the following: Group A (H. pylori[-], SPG1[normal]; reference group), Group B (H. pylori[+], SPG1[normal]), Group C (H. pylori[+], SPG1[low]) and Group D (H. pylori[-], SPG1[low]). Odds ratios (ORs) and 95% CI were calculated using multivariate logistic regression. RESULTS: There were 329 gastric cancers diagnosed an average of 13.9 years after baseline. Pre-diagnostic low SPG1 was significantly associated with increased gastric cancer risk (HR 2.68, 95% CI 1.99-3.61). Among subjects with both SPG1 and H. pylori serology, groups B, C and D had increased gastric cancer ORs (95% CI) of 1.79 (1.21-2.64), 3.85 (2.36-6.28) and 6.35 (2.20-18.34), respectively. CagA seropositives had significantly higher ORs than CagA seronegatives within group B (Pheterogeneity = 0.01). For groups B and C, repeat SPG1 level at 3 years did not further stratify gastric cancer risk. CONCLUSIONS: Low SPG1 was associated with increased gastric cancer risk in our large Finnish cohort. A single measurement of SPG1 along with H. pylori whole cell and CagA serology provides potentially useful prediction of gastric cancer risk.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Song M, Camargo MC, Weinstein SJ, et al. Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males. Aliment Pharmacol Ther. 2017. PMID: 29243850. doi:10.1111/apt.14471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。